Dosing Calculation for Co-amoxiclav 457mg/5mL
For a 43.8 kg pediatric patient requiring 90 mg/kg/day of amoxicillin, administer 18.3 mL of co-amoxiclav 457mg/5mL suspension twice daily (9.15 mL per dose).
Calculation Breakdown
The FDA-approved dosing for the high-dose co-amoxiclav formulation (600 mg/42.9 mg per 5 mL) explicitly states 90 mg/kg/day divided every 12 hours for pediatric patients 3 months and older 1. Your preparation (457 mg/5 mL) contains less amoxicillin per volume, requiring adjustment.
Step-by-step calculation:
- Total daily dose needed: 43.8 kg × 90 mg/kg = 3,942 mg amoxicillin per day
- Dose per administration (twice daily): 3,942 mg ÷ 2 = 1,971 mg per dose
- Volume per dose: (1,971 mg ÷ 457 mg) × 5 mL = 21.6 mL per dose
- Total daily volume: 21.6 mL × 2 = 43.2 mL per day
However, note the critical formulation discrepancy: The 457 mg/5 mL preparation you're using is NOT the FDA-approved high-dose formulation. The FDA label explicitly warns that different co-amoxiclav suspensions are not interchangeable due to varying clavulanate ratios 1.
Critical Formulation Considerations
The FDA-approved 600 mg/42.9 mg per 5 mL formulation is specifically designed for 90 mg/kg/day dosing with appropriate clavulanate levels (6.4 mg/kg/day) 1. Your 457 mg/5 mL preparation likely has a different clavulanate ratio, which may affect:
- β-lactamase inhibition adequacy
- Gastrointestinal tolerability
- Clinical efficacy against resistant pathogens
If treating moderate-to-severe infection, recent antibiotic exposure, daycare attendance, or age <2 years - conditions where high-dose therapy is indicated 2 - strongly consider obtaining the FDA-approved 600 mg/42.9 mg per 5 mL formulation instead.
Administration Guidelines
- Give at the start of meals to minimize gastrointestinal intolerance and enhance clavulanate absorption 1
- Shake suspension vigorously before each dose 1
- Duration: 10 days for most indications 3, 2
- Monitor for clinical improvement within 48-72 hours 3
Common Pitfall
The most frequent error is assuming all co-amoxiclav suspensions are equivalent. They are not 1. The clavulanate component varies significantly between formulations, affecting coverage of β-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis - key pathogens in pediatric respiratory infections 2, 4.